Cerebrospinal fluid ACTH and cortisol in opsoclonus-myoclonus: effect of therapy
- PMID: 16087057
- DOI: 10.1016/j.pediatrneurol.2005.03.004
Cerebrospinal fluid ACTH and cortisol in opsoclonus-myoclonus: effect of therapy
Abstract
Opsoclonus-myoclonus syndrome is one of a few corticotropin (ACTH)-responsive central nervous system disorders of childhood. We measured cerebrospinal fluid ACTH and cortisol in 69 children with opsoclonus-myoclonus and 25 age- and sex-matched control subjects to determine endogenous levels and look for hypothesized differential hormonal effects of ACTH and corticosteroid treatment. Cerebrospinal fluid cortisol was 10-fold higher with ACTH treatment (n = 26), but was unchanged with oral steroid treatment (n = 18) or no treatment (n = 25). It was significantly higher in children receiving daily high-dose ACTH than alternate day ACTH. In ACTH-treated children, cerebrospinal fluid and serum cortisol were highly correlated (r = 0.96, P = 0.0001), with a mean ratio of cerebrospinal fluid to serum cortisol of approximately 1:10. Cerebrospinal fluid ACTH concentration did not differ significantly between untreated opsoclonus-myoclonus and control subjects but was lower with ACTH (-29%) or steroid treatment (-36%), suggesting feedback inhibition of ACTH release. These data delineate differences in the central effects of ACTH and corticosteroid therapy, as well as between high and low ACTH doses, and support the integrity of the brain-adrenal axis in pediatric opsoclonus-myoclonus.
Similar articles
-
Cerebrospinal fluid 5-hydroxyindoleacetic acid and homovanillic acid in the pediatric opsoclonus-myoclonus syndrome.Ann Neurol. 1995 Feb;37(2):189-97. doi: 10.1002/ana.410370209. Ann Neurol. 1995. PMID: 7531417 Clinical Trial.
-
Therapeutic down-regulation of central and peripheral B-cell-activating factor (BAFF) production in pediatric opsoclonus-myoclonus syndrome.Cytokine. 2008 Oct;44(1):26-32. doi: 10.1016/j.cyto.2008.06.001. Epub 2008 Aug 9. Cytokine. 2008. PMID: 18675552
-
Monoaminergic effects of high-dose corticotropin in corticotropin-responsive pediatric opsoclonus-myoclonus.Mov Disord. 1998 May;13(3):522-8. doi: 10.1002/mds.870130323. Mov Disord. 1998. PMID: 9613746
-
Antibodies to ACTH in opsoclonus-myoclonus.Neuropediatrics. 1993 Jun;24(3):131-3. doi: 10.1055/s-2008-1071529. Neuropediatrics. 1993. PMID: 8395029 Review.
-
[Opsoclonus-myoclonus syndrome].Medicina (B Aires). 2009;69(1 Pt 1):64-70. Medicina (B Aires). 2009. PMID: 19240003 Review. Spanish.
Cited by
-
Mechanisms of action of adrenocorticotropic hormone and other melanocortins relevant to the clinical management of patients with multiple sclerosis.Mult Scler. 2013 Feb;19(2):130-6. doi: 10.1177/1352458512458844. Epub 2012 Oct 3. Mult Scler. 2013. PMID: 23034287 Free PMC article. Review.
-
Treatment of acute relapses in multiple sclerosis.Neurotherapeutics. 2013 Jan;10(1):97-105. doi: 10.1007/s13311-012-0160-7. Neurotherapeutics. 2013. PMID: 23229226 Free PMC article. Review.
-
Treatment of moderately to severely active systemic lupus erythematosus with adrenocorticotropic hormone: a single-site, open-label trial.Lupus. 2014 Aug;23(9):905-12. doi: 10.1177/0961203314532562. Epub 2014 May 2. Lupus. 2014. PMID: 24795067 Free PMC article. Clinical Trial.
-
Melanocortins, Melanocortin Receptors and Multiple Sclerosis.Brain Sci. 2017 Aug 14;7(8):104. doi: 10.3390/brainsci7080104. Brain Sci. 2017. PMID: 28805746 Free PMC article. Review.
-
A compound heterozygous missense mutation and a large deletion in the KCTD7 gene presenting as an opsoclonus-myoclonus ataxia-like syndrome.J Neurol. 2012 Dec;259(12):2590-8. doi: 10.1007/s00415-012-6545-z. Epub 2012 May 26. J Neurol. 2012. PMID: 22638565
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources